Page 48 - ITPS-8-2

INNOSC Theranostics and
Pharmacological Sciences MDD biomarkers: Clinical implications

infliximab for treatment-resistant depression: The role doi: 10.1523/JNEUROSCI.1309-11.2011
of baseline inflammatory biomarkers. JAMA Psychiatry. 23. Ruland T, Chan MK, Stocki P, et al. Molecular serum signature
2013;70(1):31-41. of treatment resistant depression. Psychopharmacology
doi: 10.1001/2013.jamapsychiatry.4 (Berl). 2016;233(15-16):3051-3059.
14. Arteaga-Henríquez G, Simon MS, Burger B, et al. Low- doi: 10.1007/s00213-016-4348-0
grade inflammation as a predictor of antidepressant and 24. Uher R, Tansey KE, Dew T, et al. An inflammatory
anti-inflammatory therapy response in MDD patients: biomarker as a differential predictor of outcome of
A systematic review of the literature in combination depression treatment with escitalopram and nortriptyline.
with an analysis of experimental data collected in the Am J Psychiatry. 2014;171:1278-1286.
EU-MOODINFLAME consortium. Front Psychiatry.
2019;10:458. doi: 10.1176/appi.ajp.2014.14010094
doi: 10.3389/fpsyt.2019.00458 25. Druzhkova T, Pochigaeva K, Kazimirova E, et al. Acute stress
response to a cognitive task in patients with major depressive
15. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic disorder: Potential metabolic and proinflammatory
plasticity and depression: New insights from stress and biomarkers. Metab Brain Dis. 2019;34:621-629.
rapid-acting antidepressants. Nat Med. 2016;22(3):238-249.
doi: 10.1007/s11011-018-0367-3
doi: 10.1038/nm.4050
26. Gadad BS Jha MK, Grannemann BD, Mayes TL, Trivedi MH.
16. Autry AE, Monteggia LM. Brain-derived neurotrophic Proteomics profiling reveals inflammatory biomarkers
factor and neuropsychiatric disorders. Pharmacol Rev. of antidepressant treatment response: Findings from the
2012;64(2):238-258. CO-MED trial. J Psychiatr Res. 2017;94:1-6.
doi: 10.1124/pr.111.005108 doi: 10.1016/j.jpsychires.2017.05.012
17. Pariante CM, Lightman SL. The HPA axis in major 27. Bot M, Jansen R, Lamers F, et al. Serum proteomic
depression: Classical theories and new developments. profiling of major depressive disorder. Transl Psychiatry.
Trends Neurosci. 2008;31(9):464-468. 2015;5(7):e599-e599.
doi: 10.1016/j.tins.2008.06.006 doi: 10.1038/tp.2015.88
18. Strawbridge R, Arnone D, Danese A, Papadopoulos A, 28. Ramsey JM, Cooper JD, Bot M, et al. Sex differences
Vives AH, Cleare A. Inflammation and clinical response in serum markers of major depressive disorder in the
to treatment in depression: A meta-analysis. Eur Netherlands study of depression and anxiety (NESDA).
Neuropsychopharmacol. 2015;25(10):1532-1543. PLoS One. 2016;11(5):e0156624.
doi: 10.1016/j.euroneuro.2015.06.007 doi: 10.1371/journal.pone.0156624
19. Lacono LL, Bussone S, Andolina D, Tambelli R, Troisi A, 29. Carboni L, McCarthy DJ, Delafont B, et al. Biomarkers
Carola V. Dissecting major depression: The role of for response in major depression: Comparing paroxetine
blood biomarkers and adverse childhood experiences and venlafaxine from two randomised placebo-controlled
in distinguishing clinical subgroups. J Affect Disord. clinical studies. Transl Psychiatry. 2019;9(1):182.
2020;276:351-360. doi: 10.1038/s41398-019-0521-7
doi: 10.1016/j.jad.2020.07.034 30. Park MY, Kim HS, Lee M, et al. FAM19A5, a brain-specific
20. Kang HJ, Stewart R, Bae KY, et al. Predictive value of chemokine, inhibits RANKL-induced osteoclast formation
homocysteine for depression after acute coronary syndrome. through formyl peptide receptor 2. Sci Rep. 2017;7(1):15575.
Oncotarget. 2016;7(42):69032-6940. doi: 10.1038/s41598-017-15586-0
doi: 10.18632/oncotarget.11966 31. Han KM, Tae WS, Kim A, et al. Serum FAM19A5
21. Tolahunase MR, Sagar R, Faiq M, Dada R. Yoga- levels: A novel biomarker for neuroinflammation and
and meditation-based lifestyle intervention increases neurodegeneration in major depressive disorder. Brain
neuroplasticity and reduces severity of major depressive Behav Immun. 2020;87:852-859.
disorder: A randomized controlled trial. Restor Neurol doi: 10.1016/j.bbi.2020.03.021
Neurosci. 2018;36(3):423-442.
32. Yang CR, Liang R, Liu Y, et al. Upregulation of proBDNF/
doi: 10.3233/RNN-170810 p75NTR signaling in immune cells and its correlation with
22. Blugeot A, Rivat C, Bouvier E, et al. Vulnerability to inflammatory markers in patients with major depression.
depression: From brain neuroplasticity to identification of FASEB J. 2024;38(1):e23312.
biomarkers. J Neurosci. 2011;31(36):12889-12899. doi: 10.1096/fj.202301140RR

Volume 8 Issue 2 (2025) 42 doi: 10.36922/itps.4404